FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kurt Zimmermann

Research Profile

Chemicals & Drugs

Concepts & Ideas

Structure-Activity Relationship

Living Beings

Procedures

Anatomy

Tumor Cell Line

Genes & Molecular Sequences

Molecular Structure

Co-author Network

Publications

TOP 3
Petra Ross-Macdonald; Anthony Sampognaro; Mark Saulnier; Nathan Siemers; Charles Tilford; George Trainor; Amy Truong; Dolatrai Vyas; Joan Carboni; Heshani de Silva; Marco Dodier; David Frennesson; Marco Gottardis; Ann Greer; Aiqing He; RuiRu Ji; Frank Lee; Krista Menard; Isaac Neuhaus; Vishal Patel; Kurt Zimmermann; Mark Wittman
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.
Upender Velaparthi; Mark G Saulnier; Mark Wittman; Peiying Liu; David B Frennesson; Kurt Zimmermann; Joan M Carboni; Marco Gottardis; Aixin Li; Ann Greer; Wendy Clarke; Zheng Yang; Krista Menard; Francis Y Lee; George Trainor; Dolatrai M Vyas
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.
Kurt Zimmermann; Mark Wittman; Mark G Saulnier; Upender Velaparthi; Xiaopeng Sang; David B Frennesson; Charles Struzynski; Steven P Seitz; Liqi He; Joan M Carboni; Aixin Li; Ann F Greer; Marco Gottardis; Ricardo M Attar; Zheng Yang; Praveen Balimane; Lorell N Discenza; Francis Y Lee; Michael Sinz; Sean Kim; Dolatrai Vyas
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kurt Zimmermann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Petra Ross-Macdonald; Anthony Sampognaro; Mark Saulnier; Nathan Siemers; Charles Tilford; George Trainor; Amy Truong; Dolatrai Vyas; Joan Carboni; Heshani de Silva; Marco Dodier; David Frennesson; Marco Gottardis; Ann Greer; Aiqing He; RuiRu Ji; Frank Lee; Krista Menard; Isaac Neuhaus; Vishal Patel; Kurt Zimmermann; Mark Wittman
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.
Bioorganic & medicinal chemistry 2012;20(6):1961-72.
2010: Upender Velaparthi; Mark G Saulnier; Mark Wittman; Peiying Liu; David B Frennesson; Kurt Zimmermann; Joan M Carboni; Marco Gottardis; Aixin Li; Ann Greer; Wendy Clarke; Zheng Yang; Krista Menard; Francis Y Lee; George Trainor; Dolatrai M Vyas
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.
Bioorganic & medicinal chemistry letters 2010;20(10):3182-5.
2010: Kurt Zimmermann; Mark Wittman; Mark G Saulnier; Upender Velaparthi; Xiaopeng Sang; David B Frennesson; Charles Struzynski; Steven P Seitz; Liqi He; Joan M Carboni; Aixin Li; Ann F Greer; Marco Gottardis; Ricardo M Attar; Zheng Yang; Praveen Balimane; Lorell N Discenza; Francis Y Lee; Michael Sinz; Sean Kim; Dolatrai Vyas
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
Bioorganic & medicinal chemistry letters 2010;20(5):1744-8.
2008: Upender Velaparthi; Mark Wittman; Peiying Liu; Joan M Carboni; Francis Y Lee; Ricardo Attar; Praveen Balimane; Wendy Clarke; Michael W Sinz; Warren Hurlburt; Karishma Patel; Lorell Discenza; Sean Kim; Marco Gottardis; Ann Greer; Aixin Li; Mark Saulnier; Zheng Yang; Kurt Zimmermann; George Trainor; Dolatrai Vyas
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Journal of medicinal chemistry 2008;51(19):5897-900.
2008: Kurt Zimmermann; Mark D Wittman; Mark G Saulnier; Upender Velaparthi; David R Langley; Xiaopeng Sang; David Frennesson; Joan Carboni; Aixin Li; Ann Greer; Marco Gottardis; Ricardo M Attar; Zheng Yang; Praveen Balimane; Lorell N Discenza; Dolatrai Vyas
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(14):4075-80.
2008: Mark G Saulnier; David B Frennesson; Mark Wittman; Kurt Zimmermann; Upender Velaparthi; David R Langley; Charles Struzynski; Xiaopeng Sang; Joan M Carboni; Aixin Li; Ann Greer; Zheng Yang; Praveen Balimane; Marco Gottardis; Ricardo M Attar; Dolatrai M Vyas
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.
Bioorganic & medicinal chemistry letters 2008;18(5):1702-7.
2007: Upender Velaparthi; Mark Wittman; Peiying Liu; Karen M Stoffan; Kurt Zimmermann; Xiaopeng Sang; Joan M Carboni; Aixin Li; Ricardo M Attar; Marco Gottardis; Ann Greer; ChiehYing Y Chang; Bruce L Jacobsen; John S Sack; Yax Sun; David R Langley; Balu N Balasubramanian; Dolatrai M Vyas
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).
Bioorganic & medicinal chemistry letters 2007;17(8):2317-21.
2005: Joan M Carboni; Adrian V Lee; Darryl L Hadsell; Bruce R Rowley; Francis Y Lee; David K Bol; Amy Camuso; Marco Gottardis; Ann Greer; Ching Ping Ho; Warren Hurlburt; Aixin Li; Mark G Saulnier; Upender Velaparthi; Cindy Wang; Mei-Li Wen; Richard A Westhouse; Mark Wittman; Kurt Zimmermann; Brent A Rupnow; Tze Wai Wong
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.
Cancer research 2005;65(9):3781-7.
2005: Mark G Saulnier; Balu N Balasubramanian; Byron H Long; David B Frennesson; Edward Ruediger; Kurt Zimmermann; Jeffrey T Eummer; Denis R St Laurent; Karen M Stoffan; B Narasimhulu Naidu; Mikael Mahler; Francis Beaulieu; Carol Bachand; Francis Y Lee; Craig R Fairchild; Linda K Stadnick; William C Rose; Carola Solomon; Henry Wong; Alain Martel; John J Wright; Robert Kramer; David Langley; Dolatrai M Vyas
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.
Journal of medicinal chemistry 2005;48(7):2258-61.
2005: Mark G Saulnier; David Langley; David B Frennesson; Byron H Long; Stella Huang; Qi Gao; Dedong Wu; Craig R Fairchild; Edward Ruediger; Kurt Zimmermann; Denis R St Laurent; Balu N Balasubramanian; Dolatrai M Vyas
Novel 3',6'-anhydro and N12,N13-bridged glycosylated fluoroindolo[2,3-a]carbazoles as topoisomerase I inhibitors. Fluorine as a leaving group from sp3 carbon.
Organic letters 2005;7(7):1271-4.
2004: Balu N Balasubramanian; Denis R St Laurent; Mark G Saulnier; Byron H Long; Carol Bachand; Francis Beaulieu; Wendy Clarke; Milind Deshpande; Jeffrey Eummer; Craig R Fairchild; David B Frennesson; Robert Kramer; Francis Y Lee; Mikael Mahler; Alain Martel; B Narasimhulu Naidu; William C Rose; John Russell; Edward Ruediger; Carola Solomon; Karen M Stoffan; Henry Wong; John J Wright; Kurt Zimmermann; Dolatrai M Vyas
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Journal of medicinal chemistry 2004;47(7):1609-12.